FGP
REGN icon

Freestone Grove Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Freestone Grove Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-30,625
Closed -$23.7M – 1267
2026
Q1 		$23.7M Sell
30,625
-10,784
-26% -$8.26M 0.17% 191
2025
Q4 		$32M Sell
41,409
-22,820
-36% -$15.5M 0.23% 144
2025
Q3 		$36.1M Buy
64,229
+20,818
+48% +$11.8M 0.27% 136
2025
Q2 		$22.8M Buy
+43,411
New +$24.2M 0.17% 185

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Freestone Grove Partners's REGN Position: Q2 2026 in Review

Freestone Grove Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 30,625 shares — an estimated $23.7M sold.

Freestone Grove Partners first reported a position in REGN in Q2 2025 and held it in 4 quarters. The position peaked at $36.1M in Q3 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Freestone Grove Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 30,625 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $23.7M.
  • Freestone Grove Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and held it in 4 quarters.
  • Freestone Grove Partners's Regeneron Pharmaceuticals position peaked at $36.1M in Q3 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.